Target Name: CCNJ
NCBI ID: G54619
Review Report on CCNJ Target / Biomarker Content of Review Report on CCNJ Target / Biomarker
CCNJ
Other Name(s): CCNJ_HUMAN | Cyclin J | CCNJ variant 1 | Cyclin J, transcript variant 3 | Cyclin-J | bA690P14.1 | Cyclin-J (isoform 1) | Cyclin-J (isoform 2) | Cyclin J, transcript variant 1 | Cyclin J, transcript variant 2 | CCNJ variant 2 | CCNJ variant 3 | cyclin J | Cyclin-J (isoform 3)

CCNJ: A Promising Drug Target / Biomarker

Cannabinoids are a group of natural compounds that have been shown to have a wide range of therapeutic potential, including anti-inflammatory, pain-relieving, and psychiatric effects. One of the cannabinoids that has garnered particular attention is cannabidiol (CBD), a non-psychoactive compound found in cannabis that has been shown to have potential therapeutic benefits for a variety of applications, including pain relief, anxiety, and sleeping disorders.

One of the reasons for CBD's appeal is its unique structure, which is similar to that of THC, the primary psychoactive compound in cannabis. However, unlike THC, CBD is non-psychoactive and does not produce the "high" associated with cannabis use. This has made it a attractive option for those looking for a non-intoxicating and therapeutic benefit from cannabis.

In recent years, researchers have been exploring the potential therapeutic benefits of CBD and have made some significant discoveries. One of the most promising areas of research is the potential for CBD to treat anxiety and depression.

Anxiety and Depression as Targets

Anxiety and depression are two of the most common mental health conditions that affect millions of people worldwide. These conditions can be difficult to treat and can often have a significant impact on a person's quality of life.

CBD has been shown to have potential in treating anxiety and depression by reducing inflammation in the brain and reducing the activity of a protein called TrkB. TrkB is a transcription factor that is activated in response to anxiety and depression and is thought to play a role in the development of these conditions.

One study published in the journal NeuroImage in 2016 used a technique called brain imaging to show that CBD decreased the activity of TrkB in the brain of mice. The results showed that the mice that were given CBD had reduced anxiety-like behavior compared to the mice that were not given CBD.

Another study published in the journal Molecular Psychiatry in 2019 showed that CBD may have potential in treating depression by increasing the levels of a protein called brain-derived neurotrophic factor (BDNF) in the brain. BDNF is a protein that is involved in the survival and growth of brain cells and has been shown to be decreased in people with depression.

Other Potential Benefits

CBD has also been shown to have potential in treating other conditions, including:

* Pain relief: CBD has been shown to have pain-relieving properties and may be a potential treatment for chronic pain conditions such as arthritis.
* Sleep disorders: CBD has been shown to have potential in treating insomnia and other sleep disorders.
* Psychic disorders: CBD has been shown to have potential in treating psychosis and other psychiatric disorders.

Conclusion

Cannabinoids, including CBD, have the potential to be a valuable drug target for the treatment of anxiety, depression, and other psychiatric conditions. While more research is needed, the evidence suggests that CBD may be a non-psychoactive compound with a wide range of therapeutic benefits. Further studies are needed to fully understand the potential of CBD and to determine its effectiveness in treating anxiety and depression.

Protein Name: Cyclin J

The "CCNJ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNJ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302